Wiktor T J, Atanasiu P, Bahmanyar M, Boegel K, Cox J H, Diaz A M, Fitzgerald E A, Kuwert E, Netter R, Selimov M, Turner G, van Steenis G
Dev Biol Stand. 1978;40:171-8.
Eleven laboratories from eight countries and four continents took part in a collaborative study to evaluate experimental procedures to be used in selecting the new standard reference rabies vaccine prepared in human diploid cell cultures. The following procedures were used : (a) the NIH potency test in mice, (b) the antibody binding technique (by either mouse inoculation or the tissue culture method), (c) virus-neutralizing antibody levels in mice used for the NIH test, and (d) antibody induction in human volunteers treated with vaccine alone and in combination with human rabies gamma globulin. The four methods used for determination of rabies antibodies were mouse inoculation, rapid fluorescent focus inhibition, plaque reduction and complement fixation techniques. All results were expressed in International Units as compared to the standard WHO serum and vaccine preparations. In general, a close correlation was noted in results from different laboratories, and it was recommended that the future rabies standard vaccine should be evaluated by three testing procedures, the NIH test, the antibody-binding technique, and antibody levels in mice used for the NIH test.
来自四大洲八个国家的11个实验室参与了一项合作研究，以评估用于选择在人二倍体细胞培养物中制备的新型标准参考狂犬病疫苗的实验程序。采用了以下程序：(a) 小鼠的NIH效价试验；(b) 抗体结合技术（通过小鼠接种或组织培养方法）；(c) 用于NIH试验的小鼠体内病毒中和抗体水平；(d) 单独使用疫苗以及与狂犬病γ球蛋白联合使用疫苗时，对人类志愿者抗体诱导情况。用于测定狂犬病抗体的四种方法为小鼠接种、快速荧光灶抑制、蚀斑减少和补体结合技术。与世界卫生组织标准血清和疫苗制剂相比，所有结果均以国际单位表示。总体而言，不同实验室的结果显示出密切相关性，建议未来狂犬病标准疫苗应通过三种检测程序进行评估，即NIH试验、抗体结合技术以及用于NIH试验的小鼠体内抗体水平检测。
